MYOVANT SCIENCES

Redefining Care

FOR WOMEN
FOR MEN
FOR YOU

Third Fiscal Quarter 2021 Earnings Conference Call

January 26, 2022

Introduction

Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.

Forward-Looking Statements

This presentation contains forward-looking statements, including without limitation, statements related to: Myovant's aspiration to redefine care for women and for men; Myovant's expected upcoming milestones; Myovant's 2022 objectives; the potential benefits and commercial opportunities of Myovant's drug products; the expected benefits and success of collaborations with Myovant's collaboration partners; Myovant's corporate and business development opportunities, including its potential partnership for international rights to relugolix in oncology; the timing and expectations of Myovant's clinical data announcement, regulatory filings, potential approvals and commercial launches; Myovant's business strategies, financial condition and trends, competitive position, potential growth opportunities, and expectations or probabilities for success, including the statements about ORGOVYX being positioned to become the androgen deprivation therapy standard of care over time, MYFEMBREE's potential to transform multiple hormone-driven diseases in large populations in women's health, and the plans to expand pipeline of potential medicines. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "likely," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "to be," "will," "would," or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identifying words. Myovant cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors known and unknown that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those risks discussed under the heading "Risk Factors" in Myovant Sciences' Quarterly Report on Form 10-Q filed on January 26, 2022, as such risk factors may be amended, supplemented or superseded from time to time. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for its management to predict all risk factors, nor can Myovant assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, Myovant undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Business Update

Dave Marek
Chief Executive Officer
Myovant Sciences, Inc.

Recent Key Developments

Commercial Execution

- Fiscal Q3 2021 revenues of $54.4M; net product revenues of $29.3M, composed of:
  - ORGOVYX-U.S.: $24.4M
  - MYFEMBREE-U.S.: $2.4M
  - Gedeon Richter product supply and royalty: $2.4M
- Notable launch progress
  - ORGOVYX volume increased 40% vs. fiscal Q2 2021
  - MYFEMBREE NBRx share at 45% in Dec 2021, compared to 20% in Sep 2021[1]
  - RYEQO launched by Richter in 12 countries since July 2021 EC approval

Business Development

- Engaged in formal process to assess partnership opportunities with multiple interested parties for international[2] rights to relugolix in oncology
  - Continue to target a partnership announcement prior to potential EC approval for relugolix in prostate cancer, expected in mid-calendar year 2022

Financial

- Well-capitalized with cash and committed financing of $569.1 million as of December 31, 2021
- Strong financial position to support ORGOVYX and MYFEMBREE launches while seeking pipeline opportunities focused on women's health and oncology

NBRx = New-to-brand prescription share; EC = European Commission

(1) Among GnRH antagonists FDA-approved for uterine fibroids. Data from Symphony Health.

(2) Outside U.S. and Canada; excluding Japan, China, Hong Kong, Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam.

2022 Objectives

Delivering for Today **with Commercial Execution**

- Drive ORGOVYX growth by increasing breadth and depth of HCP adoption & increasing patient engagement
- Accelerate MYFEMBREE uptake in uterine fibroids by building HCP coverage confidence and activating patients
- Launch MYFFEMBREE in endometriosis, if approved

While Building for Tomorrow **through Pipeline Expansion**

- Complete two-year SPIRIT LTE in endometriosis and initiate other relugolix lifecycle studies to strengthen market positioning
- Submit sNDA for two-year randomized withdrawal study in uterine fibroids
- Advance MVT-602 clinical development
- Expand geographically through international partnership for relugolix in oncology & Richter MAA submission in endometriosis
- Explore business development opportunities, focused on urology, oncology, and women's health

HCP = Healthcare provider; LTE = Long-term extension; sNDA = Supplemental New Drug Application; MAA = Marketing Authorisation Application

Commercial Update

Lauren Merendino
Chief Commercial Officer
Myovant Sciences, Inc.

ORGOVYX®
Launch Update

Launch-to-Date[1] Net Revenues of $57.2 Million

ORGOVYX® (relugolix) 120 mg tablets

~11,000 Patients

estimated cumulative patients treated since launch[1,2]

$24.4 Million

net product revenues recorded in fiscal Q3 2021

40%

sequential volume growth vs. fiscal Q2 2021

(1) Through December 31, 2021, the end of Myovant's third fiscal quarter 2021. ORGOVYX was launched on January 3, 2021, in Myovant's fourth quarter of fiscal year 2020.
(2) Includes patients on free and commercial volumes, excludes patients utilizing product samples, which were initially distributed beginning in November 2021.

MYOVANT SCIENCES

ORGOVYX New Patient Starts[1] Steadily Increased

Estimated Cumulative Patients Treated with ORGOVYX

(includes patients on free and commercial drug, excludes patients utilizing product samples)



- 3,000+ additional patients treated from Oct to Dec 2021
- Sampling initiated in Nov 2021; free trial program phased out
- Given wind down of free trial program, Dec patient starts do not include any new patients from the free trial program
- Diversity of patients across multiple advanced prostate cancer settings

(1) Includes patients on free and commercial drug, excludes patients utilizing product samples.

MYOVANT SCIENCES

New Sample Program Initiated to Facilitate Patient Starts at Point-of-Care



- Enables providers to start patients on ORGOVYX immediately upon treatment decision to evaluate efficacy and tolerability and to gain experience
- Over 2,250 monthly samples distributed to nearly 1,000 providers since November 2021
- Vouchers available to practices where samples are not permitted

Treatment Center Adoption Continuing to Steadily Increase; ~1,800 Have Prescribed ORGOVYX Since Launch

Cumulative Treatment Centers Since Launch



- ~300 additional treatment centers placed initial orders from Oct to Dec 2021
- 89% treatment center re-order rate
- ~60% of volumes prescribed by urologists; ~40% prescribed by oncologists
- ~75% of commercial volume dispensed through specialty distributor channel

MYOVANT SCIENCES

190 Million Commercial and Part D Lives Covered[1]

144 Million
Commercial Lives Covered



46 Million
Medicare Part D Lives Covered



17 Million More Commercial and Part D Lives Gained Coverage Since October

Note: Percentages of covered lives based on 178 million total Commercial/Exchange lives (including VA and DoD/Tricare) and 47 million total Medicare Part D lives. Source: MMIT December 2021. Including commercial, Medicare Part D, Medicaid, and Veterans Administration/Department of Defense lives, 258 million total lives had coverage for ORGOVYX as of January 2022.

(1) As of January 2022.

(2) Coverage can be obtained via medical/formulary exception process.

MYOVANT SCIENCES

Prostate Cancer is the 2nd Most Common Cancer Affecting Men[1]

~3M men diagnosed with prostate cancer alive in the U.S.[2]

~300K men in U.S. expected to be treated with ADT in 2022[3]

~100K men in U.S. expected to initiate ADT in 2022[3]

Among associated risk factors, **2 out of 3 men** have cardiovascular disease risk[4,5]

ADT = Androgen deprivation therapy

(1) American Cancer Society.

(2) SEER Incidence Data, 2017.

(3) IQVIA National Sales Perspective data and claims data.

(4) Leong DP, Fradet V, Shayegan B, et al.. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC Study. J Urol 2020 Jun;203(6):1109-1116.

(5) Other risk factors in prostate cancer include pre-existing diabetes, which has been seen in 18% to 24% of men with prostate cancer at diagnosis, and osteoporosis, which has been seen in 9% to 53% of patients treated with ADT.

MYFEMBREE®
Launch Update

MYFEMBREE has a **BOXED WARNING for THROMBOEMBOLIC DISORDERS AND VASCULAR EVENTS**. More information including full prescribing information is available at whttps://www.myovant.com/wp-content/uploads/2021/05/Approved-MYFEMBREE-PI-and-PPI_26May2021.pdf.

Encouraging Early Indicators for Reaching Women with Uterine Fibroids

Myfembree®
(relugolix, estradiol, and norethindrone acetate) tablets
40 mg, 1 mg, 0.5 mg

~1,400 Patients

initiated treatment on free or commercial drug[1]

45% NBRx Share

of GnRH antagonist therapies FDA-approved for uterine fibroids[2]

~800 Prescribers

including 58% who had not previously prescribed ORIAHNN[2]

Launch-to-date[2] net revenues of $4.1 million; fiscal Q3 2021 net revenues of $2.4M

NBRx = New-to-brand prescription
(1) Through November 2021. Includes patients on MYFEMBREE free goods programs and commercial volumes. Excludes patients using product samples.
(2) Through December 2021.
ORIAHNN is a registered trademark of Abbvie Inc.

MYOVANT SCIENCES

Early Progress Educating Providers Leading to Increased Prescriber Awareness

~134K HCP calls conducted[1]

85% High- and medium-priority target prescribers reached

HCP AIDED AWARENESS[2]

31% Pre-Launch → **89%** Dec 2021

HCP UNAIDED AWARENESS[2]

1% Pre-Launch → **41%** Dec 2021

Note: All data points are from launch through January 4, 2022, unless otherwise indicated, and reflect combined efforts of Myovant and Pfizer.
HCP = Healthcare provider
(1) HCP calls defined as an in-person or virtual discussion regarding the MYFEMBREE safety and efficacy profile for the treatment of uterine fibroids with an HCP who is directly involved in patient care.
(2) December 2021 interim Awareness Trial Usage (ATU) report.

MYOVANT SCIENCES

MYFEMBREE Rapidly Capturing Significant New-to-Brand Prescription Share Since Launch…

Monthly NBRx Share Among GnRH Antagonists FDA-Approved for the Treatment of Uterine Fibroids



NBRx = New-to-brand prescription; GnRH = Gonadotropin-releasing hormone; FDA = U.S. Food and Drug Administration
Data from Symphony Health.
ORIAHNN is a registered trademark of Abbvie Inc.

MYOVANT SCIENCES

…While Growing the GnRH Antagonist Market[1] for Uterine Fibroids

Cumulative Monthly MYFEMBREE Prescribers From Launch Through Dec 2021



4-Week Moving Average TRx for GnRH Antagonists for Uterine Fibroids Since MYFEMBREE Launch

GnRH = Gonadotropin-releasing hormone; TRx = Total prescriptions; FDA = U.S. Food and Drug Administration
TRx data from Symphony Health, through December 31, 2021.
(1) Among GnRH antagonists FDA-approved for use in uterine fibroids.

MYOVANT SCIENCES

148 Million Commercial Lives Covered[1]

109 Million
Commercial Lives Covered as of October 2021



148 Million
Commercial Lives Covered as of January 2022



39 Million More Commercial Lives Gained Coverage Since October

Note: Percentages of covered lives based on 177.8 million total Commercial/Exchange lives, including VA and DoD/Tricare. Source: MMIT December 2021.
(1) As of January 2022.
(2) Coverage can be obtained via medical/formulary exception process.

MYOVANT SCIENCES

MYFEMBREE* Has Potential to Address Significant Unmet Need in Endometriosis

***MYFEMBREE is not FDA-approved for use in endometriosis-associated pain**



COMMON SYMPTOMS

- **Pain**
- **Painful Intercourse**
- **Bowel Symptoms**
- **Fatigue**
- **Infertility**

MEDICAL NEED (U.S. WOMEN AGES 15-49)[1-4]

IMPACT

3 in 4 women with endometriosis experience debilitating symptoms[1]

FDA = U.S. Food and Drug Administration

(1) Bulletti, et al. Endometriosis and infertility. *J Assist Reprod Genet*. 2010;27(8):441–447.
(2) 2010 US Census Data.
(3) Louis, et al. Incidence of endometriosis by study population and diagnostic method: the ENDO Study. *Fertil Steril*. 2011;96(2):360-365.
(4) Quaas, et al. On-label and off-label drug use in the treatment of endometriosis. *Fertil Steril*. 2015.103(3):612-625.

Endometriosis Launch Strategy to Leverage Brand Familiarity and One-Pill, Once-a-Day Dosing

	MYFEMBREE*	Other GnRH Antagonist Brands	
		AM Dose	PM Dose
UTERINE FIBROIDS	One brand, one dose, one pill, once-a-day 	300 mg E2/N	+ 300 mg
ENDOMETRIOSIS		150 mg QD OR 200 mg	+ 200 mg

*MYFEMBREE is not FDA-approved for use in endometriosis-associated pain.

FDA = U.S. Food and Drug Administration; GnRH = Gonadotropin-releasing hormone; E2/N = Estradiol and norethindrone acetate; mg = milligram; QD = Once-daily
NOTE: Chart not intended to make any implied or direct comparative conclusions between MYFEMBREE and any other product; pills shown are representative and do not reflect actual size.

MYOVANT SCIENCES

Women's Health Commercial Opportunity Driven by Ability to Unlock Large Patient Populations

U.S. WOMEN AGED 15-49 WITH SYMPTOMS:

Illustrative



ACOG = American College of Obstetricians and Gynecologists

(1) Represents uterine fibroid patients that are symptomatic and seeking treatment for their condition.

* **MYFEMBREE is not FDA-approved for use in endometriosis-associated pain.**

MYOVANT SCIENCES

Financial Review

Uneek Mehra
Chief Financial and Business Officer
Myovant Sciences, Inc.

Composition of Total Net Revenues

Unaudited, in millions

	Third Fiscal Quarter	
	2021 (ended December 31, 2021)	2020 (ended December 31, 2020)
Product revenue, net:		
ORGOVYX	$ 24.4	$ —
MYFEMBREE	2.4	—
Richter product supply and royalties	2.4	—
Total product revenue, net	$ 29.3	$ —
Pfizer collaboration revenue[1]	25.2	1.4
Total net revenues	$ 54.4	$ 1.4

(1) For third fiscal quarter 2021, represents partial amortization of the upfront payment and of the regulatory milestone payment associated with the FDA approval of MYFEMBREE in uterine fibroids received from Pfizer ($21.0 million and $4.2 million, respectively), pursuant to the Pfizer Collaboration and License Agreement. For third fiscal quarter 2020, represents partial amortization of the upfront payment received from Pfizer.

Income Statement Highlights

Unaudited, in millions, except per share data

	Third Fiscal Quarter	
	2021 (ended December 31, 2021)	2020 (ended December 31, 2020)
Total net revenues	$ 54.4	$ 1.4
Cost of operations:		
Cost of product revenue	4.2	—
Collaboration expense to Pfizer	12.1	—
Research and development (R&D)[1]	25.7	30.5
Selling, general and administrative (SG&A)[1]	72.1	49.2
Loss from operations	(59.7)	(78.3)
Net loss	$ (63.4)	$ (73.8)
Net loss per common share[2]	$ (0.68)	$ (0.82)

(1) In third fiscal quarter 2021, includes $3.0 million and $4.2 million of non-cash stock-based compensation in R&D and SG&A expenses, respectively. In third fiscal quarter 2020, includes $3.3 million and $3.7 million of non-cash stock-based compensation in R&D and SG&A expenses, respectively.

(2) Basic and diluted.

Summary of Cash and Committed Financing

Unaudited, in millions

	December 31, 2021
Total of cash and marketable securities	$ 527.8
Financing available from Sumitomo Dainippon Pharma (DSP)	41.3
Total of cash and committed financing from DSP	$ 569.1

Strong financial position to fund product launches and further expand pipeline

MYOVANT SCIENCES

Myovant Well-Positioned for Strong Commercial Execution and Sustainable Growth

ORGOVYX positioned to become androgen deprivation therapy standard of care over time

MYFEMBREE has potential to transform multiple hormone-driven diseases in large populations in women's health

Plan to expand pipeline of potential medicines

Strong financial position to support U.S. launch activities and pipeline expansion

Expected Upcoming Milestones

MYFEMBREE FDA submission of LIBERTY randomized withdrawal study results, including 2-year BMD data, in Q1 2022[1]

Two-year data from SPIRIT program in endometriosis in Q1 2022[1]

FDA decision on endometriosis sNDA filing by May 6, 2022

European Commission decision on advanced prostate cancer filing in mid-2022[1]

MAA submission for endometriosis in 2022[1,2]

FDA = U.S. Food and Drug Administration; BMD = Bone mineral density; sNDA = Supplemental New Drug Application; MAA = Marketing Authorisation Application

(1) Calendar year.

(2) Richter to complete MAA submission.

Q&A Panel

Myovant Sciences, Inc.

Dave Marek
Chief Executive Officer

Uneek Mehra
Chief Financial & Business Officer

Lauren Merendino
Chief Commercial Officer

Juan Camilo Arjona, MD
Chief Medical Officer

MYOVANT SCIENCES

MYOVANT SCIENCES

Redefining Care.
For Women. For Men. For You.

investors@myovant.com